| Kawanjit Surapur, MD | |
|
1412 Milstead Ave Ne, Conyers, GA 30012-3877 | |
| (404) 350-0009 | |
| Not Available |
| Full Name | Kawanjit Surapur |
|---|---|
| Gender | Female |
| Speciality | Internal Medicine |
| Experience | 10 Years |
| Location | 1412 Milstead Ave Ne, Conyers, Georgia |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1093120768 | NPI | - | NPPES |
| Facility Name | Location | Facility Type |
|---|---|---|
| Piedmont Rockdale Hospital | Conyers, GA | Hospital |
| Piedmont Newton Hospital | Covington, GA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Piedmont Specialty Hospital Billing Llc | 4183986490 | 179 |
| Piedmont Providers Llc | 9830082825 | 371 |
News Archive
Slovenian Minister of Health Borut Miklavcic today officially unveiled the nation's first Novalis Tx(TM) radiosurgery platform for modern radiotherapy and radiosurgery at the Oncology Institute of Ljubljana.
Depomed, Inc. today announced that it has closed the acquisition of the U.S. rights to the NUCYNTA franchise from Janssen Pharmaceuticals, Inc. for $1.05 billion. The NUCYNTA franchise includes: NUCYNTA ER (tapentadol) extended release tablets indicated for the management of pain, including neuropathic pain associated with diabetic peripheral neuropathy (DPN), severe enough to require daily, around-the-clock, long-term opioid treatment; NUCYNTA (tapentadol), an immediate release version of tapentadol, for management of moderate to severe acute pain in adults; and NUCYNTA (tapentadol) oral solution, an approved oral form of tapentadol that has not been launched.
Experts from the world's leading lung organizations have released a position statement on electronic cigarettes, focusing on their potential adverse effects on human health and calling on governments to ban or restrict their use until their health impacts are better known.
The current FDA approved stents (CYPHER and TAXUS) have been associated with late stent thrombosis (LST) (>30days following implantation) however, the mechanisms predictive of LST are poorly understood. Pathologic studies are one of the best methods for detailed analysis of morphologic changes that occur after placement of Drug Eluting Stents to determine the causes of LST.
The study was prompted by recent reports suggesting an increased risk of complications including heart attacks, strokes, and kidney problems in patients who received aprotinin to reduce bleeding during heart bypass or valve replacement surgery.
› Verified 1 days ago
| Entity Name | Piedmont Providers Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1548273592 PECOS PAC ID: 9830082825 Enrollment ID: O20040204000321 |
News Archive
Slovenian Minister of Health Borut Miklavcic today officially unveiled the nation's first Novalis Tx(TM) radiosurgery platform for modern radiotherapy and radiosurgery at the Oncology Institute of Ljubljana.
Depomed, Inc. today announced that it has closed the acquisition of the U.S. rights to the NUCYNTA franchise from Janssen Pharmaceuticals, Inc. for $1.05 billion. The NUCYNTA franchise includes: NUCYNTA ER (tapentadol) extended release tablets indicated for the management of pain, including neuropathic pain associated with diabetic peripheral neuropathy (DPN), severe enough to require daily, around-the-clock, long-term opioid treatment; NUCYNTA (tapentadol), an immediate release version of tapentadol, for management of moderate to severe acute pain in adults; and NUCYNTA (tapentadol) oral solution, an approved oral form of tapentadol that has not been launched.
Experts from the world's leading lung organizations have released a position statement on electronic cigarettes, focusing on their potential adverse effects on human health and calling on governments to ban or restrict their use until their health impacts are better known.
The current FDA approved stents (CYPHER and TAXUS) have been associated with late stent thrombosis (LST) (>30days following implantation) however, the mechanisms predictive of LST are poorly understood. Pathologic studies are one of the best methods for detailed analysis of morphologic changes that occur after placement of Drug Eluting Stents to determine the causes of LST.
The study was prompted by recent reports suggesting an increased risk of complications including heart attacks, strokes, and kidney problems in patients who received aprotinin to reduce bleeding during heart bypass or valve replacement surgery.
› Verified 1 days ago
| Entity Name | Piedmont Specialty Hospital Billing Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1699290510 PECOS PAC ID: 4183986490 Enrollment ID: O20180327001180 |
News Archive
Slovenian Minister of Health Borut Miklavcic today officially unveiled the nation's first Novalis Tx(TM) radiosurgery platform for modern radiotherapy and radiosurgery at the Oncology Institute of Ljubljana.
Depomed, Inc. today announced that it has closed the acquisition of the U.S. rights to the NUCYNTA franchise from Janssen Pharmaceuticals, Inc. for $1.05 billion. The NUCYNTA franchise includes: NUCYNTA ER (tapentadol) extended release tablets indicated for the management of pain, including neuropathic pain associated with diabetic peripheral neuropathy (DPN), severe enough to require daily, around-the-clock, long-term opioid treatment; NUCYNTA (tapentadol), an immediate release version of tapentadol, for management of moderate to severe acute pain in adults; and NUCYNTA (tapentadol) oral solution, an approved oral form of tapentadol that has not been launched.
Experts from the world's leading lung organizations have released a position statement on electronic cigarettes, focusing on their potential adverse effects on human health and calling on governments to ban or restrict their use until their health impacts are better known.
The current FDA approved stents (CYPHER and TAXUS) have been associated with late stent thrombosis (LST) (>30days following implantation) however, the mechanisms predictive of LST are poorly understood. Pathologic studies are one of the best methods for detailed analysis of morphologic changes that occur after placement of Drug Eluting Stents to determine the causes of LST.
The study was prompted by recent reports suggesting an increased risk of complications including heart attacks, strokes, and kidney problems in patients who received aprotinin to reduce bleeding during heart bypass or valve replacement surgery.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Kawanjit Surapur, MD 1501 N Campbell Ave, 6th Floor, Room 6336, Tucson, AZ 85724-5040 Ph: (520) 626-2761 | Kawanjit Surapur, MD 1412 Milstead Ave Ne, Conyers, GA 30012-3877 Ph: (404) 350-0009 |
News Archive
Slovenian Minister of Health Borut Miklavcic today officially unveiled the nation's first Novalis Tx(TM) radiosurgery platform for modern radiotherapy and radiosurgery at the Oncology Institute of Ljubljana.
Depomed, Inc. today announced that it has closed the acquisition of the U.S. rights to the NUCYNTA franchise from Janssen Pharmaceuticals, Inc. for $1.05 billion. The NUCYNTA franchise includes: NUCYNTA ER (tapentadol) extended release tablets indicated for the management of pain, including neuropathic pain associated with diabetic peripheral neuropathy (DPN), severe enough to require daily, around-the-clock, long-term opioid treatment; NUCYNTA (tapentadol), an immediate release version of tapentadol, for management of moderate to severe acute pain in adults; and NUCYNTA (tapentadol) oral solution, an approved oral form of tapentadol that has not been launched.
Experts from the world's leading lung organizations have released a position statement on electronic cigarettes, focusing on their potential adverse effects on human health and calling on governments to ban or restrict their use until their health impacts are better known.
The current FDA approved stents (CYPHER and TAXUS) have been associated with late stent thrombosis (LST) (>30days following implantation) however, the mechanisms predictive of LST are poorly understood. Pathologic studies are one of the best methods for detailed analysis of morphologic changes that occur after placement of Drug Eluting Stents to determine the causes of LST.
The study was prompted by recent reports suggesting an increased risk of complications including heart attacks, strokes, and kidney problems in patients who received aprotinin to reduce bleeding during heart bypass or valve replacement surgery.
› Verified 1 days ago
Dr. Sitharam Chowdary Nandigam, MD Critical Care Medicine Medicare: Accepting Medicare Assignments Practice Location: 1612 Milstead Rd Ne, Suite A, Conyers, GA 30012 Phone: 678-413-3261 Fax: 678-413-3580 | |
Marshall David Almand, MD Critical Care Medicine Medicare: Not Enrolled in Medicare Practice Location: 1301 Well Brook Circle, Conyers, GA 30012 Phone: 770-922-3023 Fax: 770-929-1016 | |
Dr. Ekundayo Adedapo Falase, MD Critical Care Medicine Medicare: Accepting Medicare Assignments Practice Location: 1612 Milstead Rd Ne, Suite A, Conyers, GA 30012 Phone: 678-413-3261 Fax: 678-413-3580 | |
Dr. Nikky Keer, D.O. Critical Care Medicine Medicare: Accepting Medicare Assignments Practice Location: 1412 Milstead Ave Ne, Conyers, GA 30012 Phone: 770-918-3000 | |
Mr. Richard Carter, MD Critical Care Medicine Medicare: Accepting Medicare Assignments Practice Location: 1498 Klondike Rd Sw, Suite 106, Conyers, GA 30094 Phone: 770-761-7260 Fax: 678-413-1818 | |
Osarenomase Egharevba, M.D. Critical Care Medicine Medicare: Accepting Medicare Assignments Practice Location: 1412 Milstead Ave Ne, Conyers, GA 30012 Phone: 770-918-3000 |